Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 40,600
-50 (-0.12%)
May 30, 2025, 3:30 PM KST
Kolon TissueGene Company Description
Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs.
The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs.
It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018.
The company was founded in 1999 and is headquartered in Rockville, Maryland.
Kolon TissueGene, Inc.
| Country | United States |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 29 |
| CEO | Moon-jong Noh |
Contact Details
Address: 9713 Key West Avenue Rockville, Delaware 20850 United States | |
| Phone | 301-921-6000 |
| Website | tissuegene.com |
Stock Details
| Ticker Symbol | 950160 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Moon-jong Noh | Chief Executive Officer |
| Jung In Kim | Chief Financial Officer |